Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Paul Frankel"'
Autor:
Thomas P. Slavin, Anna Gardiner, Elisha Hughes, Paul Frankel, Krystal Brown, Jennifer Saam, Diana Turco, Kathleen R. Blazer, Shelly Cummings, Bita Nehoray, Ryan Bernhisel, Jeffrey N. Weitzel, Kim McGreevy, Susan Shehayeb, Kira Svirsky, Mary B. Daly, John Kidd
Publikováno v:
Breast Cancer Res Treat
PURPOSE: The prevalence, penetrance, and spectrum of pathogenic variants that predispose women to two or more breast cancers is largely unknown. METHODS: We queried clinical and genetic data from women with one or more breast cancer diagnosis who rec
Autor:
David I. Quinn, Paul Frankel, Edward M. Newman, Denice D. Tsao-Wei, Gurkamal Chatta, Primo N. Lara, Susan Groshen, Stella Khoo, John Wright, Heinz-Josef Lenz, Ana Aparicio, Przemyslaw Twardowski, David R. Gandara
Publikováno v:
Investigational New Drugs. 39:812-820
Background: Until the advent of T cell check point inhibitors standard second-line therapy for patients with metastatic urothelial cancer (mUC) was undefined. Histone deacetylase inhibitors (HDACi) have anti-cancer activity in a variety of tumor mode
Autor:
Edward M. Newman, David R. Gandara, Paul K. Paik, Ramsey D. Badawi, Ian Lanza, Jonathan W. Riess, Wilson I. Gonsalves, Primo N. Lara, Mark Dunphy, Lorenzo Nardo, David Shackelford, Simon R. Cherry, Paul Frankel, Joel Reid, Charles A. Kunos
Publikováno v:
Clinical lung cancer, vol 22, iss 1
Introduction There are currently no approved targeted therapies for lung squamous-cell carcinoma (LSCC) and KRAS-mutant lung adenocarcinoma (LUAD). About 30% of LSCC and 25% of KRAS-mutant LUAD exhibit hyperactive NRF2 pathway activation through muta
Autor:
Joanne E. Mortimer, James Waisman, Daphne Stewart, Erin Yoder, Veronica Jones, Bastiaan van der Baan, Sierra Min Li, Andrea Menicucci, Aileen Tang, Christina Yeon, Susan E. Yost, Paul Frankel, Yuan Yuan, George Somlo, Jin Sun Lee, John H. Yim, Sahra Uygun, Norma Martinez, Laura Kruper, Daniel Schmolze, Christopher Ruel, Kim Robinson
Publikováno v:
Oncologist
BackgroundIn this phase II clinical trial, we evaluated the efficacy of the nonanthracycline combination of carboplatin and nab-paclitaxel in early stage triple-negative breast cancer (TNBC).Patients and MethodsPatients with newly diagnosed stage II
Autor:
Susan E. Yost, Yuan Yuan, Christopher Ruel, Aileen Tang, Colt Egelston, Niki Patel, Norma Martinez, Jin Sun Lee, Swapnil Rajurkar, Joanne E. Mortimer, Simran Padam, Christina Yeon, Paul Frankel, Cary A. Presant, Mina S. Sedrak, Jana Portnow, Peter P. Lee
Publikováno v:
Cancer Research. 80:P3-11
Background: The combination of CDK4/6 inhibitor and aromatase inhibitor is the current standard of care therapy for patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC). Single agent immune check point inhibitor (ICI) pembrol
Autor:
Heinz Joseph Lenz, Thehang Luu, Edward M. Newman, Mihaela C. Cristea, Dean Lim, Paul Frankel, Leonard Joseph Appleman, David R. Gandara, Richard Piekarz, Brian F. Kiesel, Jan H. Beumer
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: The reported maximum tolerated dose (MTD) of single agent belinostat is 1000 mg/m(2) given days 1-5, every 21 days. Pre-clinical evidence suggests histone deacetylase inhibitors enhance retinoic acid signaling in a variety of solid tumors. W
Autor:
Daniel Schmolze, Yate-Ching Yuan, Yuan Yuan, Feng-Mao Lin, Zheng Liu, Paul Frankel, John H. Yim, Wei Wen, Zhen Chen, Susan E. Yost, Peiguo Chu
Publikováno v:
Oncotarget
Background: Metastatic triple negative breast cancer (mTNBC) is a heterogeneous disease with poor prognosis. Molecular evolution of TNBC through chemotherapy selection pressure is well recognized but poorly understood. PI3K/AKT/mTOR is one of the mos
Autor:
J Waisman, Joanne E. Mortimer, Arti Hurria, Daniel Schmolze, John H. Yim, T Treece, Y Yuan, Laura Kruper, Lusine Tumyan, M Li, Veronica Jones, Christina Yeon, Paul Frankel, G. Somlo
Publikováno v:
Cancer Research. 79:P1-15
Background: Response to neoadjuvant therapy (NT) predicts progression-free and overall survival in triple negative breast cancer (TNBC). Carboplatin has shown efficacy in patients with TNBC. The current phase II prospective neoadjuvant trial was desi
Autor:
Timothy W. Synold, Joseph Chao, Marwan Fakih, May Cho, Vincent Chung, Rohan Gupta, Paul Frankel, Jun Gong, Dean Lim, Christopher Ruel
Publikováno v:
The Oncologist
Vinorelbine tartrate is a semi‐synthetic vinca alkaloid and an inhibitor of microtubule polymerization with demonstrated antitumor properties across a spectrum of cancers. The pharmacokinetics of vinorelbine may be altered in individuals with liver
Autor:
Hussein Abdul-Hassan Tawbi, Paul Frankel, Theodore F. Logan, Sanjay Awasthi, John M. Kirkwood, Primo N. Lara, Christopher Ruel, Nikhil I. Khushalani, Lisa H. Butterfield, Ahmad A. Tarhini, Alice P. Chen, David F. McDermott, Timothy M. Kuzel, Kim Margolin, Marc S. Ernstoff
Publikováno v:
Cancer. 124:4332-4341
BACKGROUND Interleukin 2 (IL-2) is a growth factor for T and natural killer cells, promotes proinflammatory cytokines, and can lead to durable responses in patients with melanoma. Vascular endothelial growth factor (VEGF) promotes angiogenesis and mo